JY
BEAM icon

Jeff Yass’s Beam Therapeutics BEAM Stock Holding History

Jeff Yass’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.22M Sell
93,900
-106,500
-53% -$3.22M ﹤0.01% 5471
2026
Q1 		$4.78M Buy
200,400
+76,900
+62% +$2.13M ﹤0.01% 4317
2025
Q4 		$3.42M Buy
123,500
+24,500
+25% +$625K ﹤0.01% 4645
2025
Q3 		$2.4M Sell
99,000
-557,600
-85% -$11.1M ﹤0.01% 5402
2025
Q2 		$11.2M Buy
656,600
+532,200
+428% +$9.27M ﹤0.01% 2685
2025
Q1 		$2.43M Buy
124,400
+60,400
+94% +$1.58M ﹤0.01% 5106
2024
Q4 		$1.59M Sell
64,000
-48,700
-43% -$1.24M ﹤0.01% 5819
2024
Q3 		$2.76M Buy
112,700
+1,600
+1% +$41.3K ﹤0.01% 4704
2024
Q2 		$2.6M Sell
111,100
-102,400
-48% -$2.52M ﹤0.01% 4577
2024
Q1 		$7.05M Buy
213,500
+164,600
+337% +$5.13M ﹤0.01% 3114
2023
Q4 		$1.33M Sell
48,900
-183,100
-79% -$4.55M ﹤0.01% 6282
2023
Q3 		$5.58M Buy
232,000
+180,400
+350% +$4.84M ﹤0.01% 3338
2023
Q2 		$1.65M Sell
51,600
-190,700
-79% -$6.19M ﹤0.01% 5556
2023
Q1 		$7.42M Buy
242,300
+126,300
+109% +$4.98M ﹤0.01% 2886
2022
Q4 		$4.54M Buy
116,000
+59,600
+106% +$2.67M ﹤0.01% 3394
2022
Q3 		$2.69M Sell
56,400
-80,400
-59% -$4.59M ﹤0.01% 4304
2022
Q2 		$5.3M Sell
136,800
-13,800
-9% -$549K ﹤0.01% 3093
2022
Q1 		$8.63M Buy
150,600
+18,500
+14% +$1.21M ﹤0.01% 2750
2021
Q4 		$10.5M Sell
132,100
-19,900
-13% -$1.7M ﹤0.01% 2640
2021
Q3 		$13.2M Sell
152,000
-11,200
-7% -$1.13M ﹤0.01% 2490
2021
Q2 		$21M Buy
163,200
+43,100
+36% +$3.43M ﹤0.01% 1962
2021
Q1 		$9.61M Buy
120,100
+53,100
+79% +$5.05M ﹤0.01% 2827
2020
Q4 		$5.47M Buy
+67,000
New +$3.29M ﹤0.01% 3284

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Jeff Yass's BEAM Position: Q2 2026 in Review

Jeff Yass reduced its Beam Therapeutics (BEAM) stake by 25% in Q2 2026, selling an estimated $1.32M and leaving 134,679 shares worth $4.62M. The position accounts for ﹤0.01% of the portfolio, ranked #4775.

Jeff Yass first reported a position in BEAM in Q4 2020 and has held it in 23 quarters since. The position peaked at $10M in Q2 2025. 276 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Jeff Yass held 134,679 shares of Beam Therapeutics worth $4.62M as of Q2 2026.
  • Jeff Yass sold 43,712 Beam Therapeutics shares in Q2 2026, an estimated $1.32M.
  • Beam Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #4775 holding.
  • Jeff Yass first reported a position in Beam Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Jeff Yass's Beam Therapeutics position peaked at $10M in Q2 2025.
  • 276 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.